Bharat Biotech plans Rs 200–250 crore of capital expenditure in FY26 for a large vaccine manufacturing facility being developed under Sapigen Biologix Pvt Ltd in Bhubaneswar, Odisha, partly financed through debt raised from financial institutions.
Bharat Biotech mulls IPO to raise over USD 500 million
